Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and lo...
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
Assiut university, Assiut, Egypt
Northwestern University, Chicago, Illinois, United States
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
Loma Linda University Health, Loma Linda, California, United States
Maimonides Hospital, Brooklyn, New York, United States
Mount Sinai West, New York, New York, United States
University of California, Davis, Sacramento, California, United States
University of California, Irvine, Orange, California, United States
University of California, Los Angeles, Los Angeles, California, United States
Centre for Phsical Activity Research, Copenhagen, Denmark
Cardiovascular and Renal Research, Odense, Denmark
11562, Cairo, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.